Dual renin-angiotensin system blockade at optimal doses for proteinuria

Kidney International

Volumn 62, Issue 3, 2002, Pages 1020-1025

  Laverman, Gozewijn D ^a   Navis, Gerjan ^a   Henning, Robert H ^a   De Jong, Paul E ^a   De Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Add on therapy; Antiproteinuric drugs; Dose response; Lisinopril; Losartan; Nondiabefic renal disease; Progressive renal disease; Renoprotection

Indexed keywords

LISINOPRIL; LOSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HUMAN; HYPERKALEMIA; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REDUCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TITRIMETRY; VERTIGO;

EID: 0036419739     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00536.x     Document Type: Article

References (29)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
2. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
3. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
4. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
5. Gansevoort RT, de Zeeuw D, de Jong PE: Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 22:202-206, 1993
6. Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45(Suppl 45):S174-S178, 1994
7. Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45(Suppl 45):S145-S149, 1994
8. Jafar TH, Stark PC, Schmid CH, et al: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60:1131-1140, 2001
9. de Jong PE, Navis G, de Zeeuw D: Renoprotective therapy: Titration against urinary protein excretion. Lancet 354:352-353, 1999
10. Peters H, Ritz E: Dosing angiotensin II blockers-beyond blood pressure. Nephrol Dial Transplant 14:2568-2570, 1999
11. Peters H, Border WA, Noble NA: Targeting TGF-beta over-expression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1570-1580, 1998
12. Palla R, Panichi V, Finato V, et al: Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 14:35-43, 1994
13. Laverman GD, Henning RH, de Jong PE, et al: Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 38:1381-1384, 2001
14. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 32:387-392, 1998
15. Russo D, Pisani A, Balletta ME, et al: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856, 1999
16. Russo D, Minutolo R, Pisani A, et al: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38:18-25, 2001
17. Mogensen CE, Neldam S, Tikkanen I, et al: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440-1444, 2000
18. Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59:2282-2289, 2001
19. Dickerson JE, Hingorani AD, Ashby MJ, et al: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353:2008-2013, 1999
20. Bos H, Andersen S, Rossing P, et al: Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int 57(Suppl 75):S32-S37, 2000
21. Rudberg S, Aperia A, Freyschuss U, Persson B: Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 33:470-476, 1990
22. Weidmann P, Boehlen LM, de Courten M: Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 8:582-584, 1993
23. The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134:370-379, 2001
24. Bos H, Henning RH, de Boer E, et al: Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney Int 61:473-480, 2002
25. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int 45:861-867, 1994
26. Buter H, Hemmelder MH, Navis G, et al: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13:1682-1685, 1998
27. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272-279, 1989
28. Weinberg MS, Weinberg AJ, Cord R, Zappe DH: The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein secretion. J Renin-Angiotensin-Aldosterone Syst 2:S196-S198, 2001
29. Weir MR, Gray JM, Paster R, Saunders E: Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 26:124-130, 1995